SpaceWar.com - Your World At War
Iraq security forces seize 12 million benzhexol pills
Baghdad, May 5 (AFP) May 05, 2023
Iraqi security forces said Friday they had seized 12 million pills of the antispasmodic drug benzhexol, used in the treatment of Parkinson's disease but also abused as a hallucinogen.

National Security officers recovered the haul from a warehouse in east Baghdad in an operation in which they also made six arrests.

Iraqi security forces have intensified anti-narcotics operations in recent months, with several high-profile seizures reported.

Sharing borders with Syria as well as Kuwait and Saudi Arabia, Iraq has served as a major conduit for traffickers of captagon, an amphetamine which is primarily produced in Syria but has its largest market in the wealthy Gulf states.


ADVERTISEMENT




Space News from SpaceDaily.com
AI systems proposed to boost launch cadence reliability and traffic management
China debuts Long March 12A reusable rocket in Jiuquan test flight
Curiosity Blog, Sols 4750-4762: See You on the Other Side of the Sun

24/7 Energy News Coverage
Redesigned carbon framework boosts battery safety and power
Molecular catalyst switches between hydrogen and oxygen production
Project Pele microreactor reaches key milestone with first TRISO fuel delivery

Military Space News, Nuclear Weapons, Missile Defense
SDA expands Tracking Layer satellite awards and related missile defense contracts
Space Systems Command activates System Delta 80 for assured space access
Rheinmetall ICEYE Space Solutions to provide SAR reconnaissance data to German military

24/7 News Coverage
OPERA satellite data sharpens US crop and water management
Alen Space begins SATMAR satellite validation over Bay of Algeciras
Deep Arctic gas hydrate mounds host ultra deep cold seep ecosystem



All rights reserved. Copyright Agence France-Presse. Sections of the information displayed on this page (dispatches, photographs, logos) are protected by intellectual property rights owned by Agence France-Presse. As a consequence, you may not copy, reproduce, modify, transmit, publish, display or in any way commercially exploit any of the content of this section without the prior written consent of Agence France-Presse.